Long-term follow-up of conservatively managed incidental carcinoma of the prostate: A multivariate analysis of prognostic factors

Scandinavian Journal of Urology and Nephrology

Volumn 41, Issue 2, 2007, Pages 103-109

  Robinson, David ^a   Aus, Gunnar ^b   Bak, Julia ^c   Gorecki, Tomasz ^d   Herder, Anders ^c   Rosell, Johan ^c   Varenhorst, Eberhard ^c  

^a RYHOV COUNTY HOSPITAL   (Sweden)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

^d KALMAR COUNTY HOSPITAL   (Sweden)

Author keywords

Chromogranin A; Incidental carcinoma; Ki 67; p53; Prognostic factors; Prostate cancer; Survival

Indexed keywords

CHROMOGRANIN A; KI 67 ANTIGEN; PROTEIN P53; SEROTONIN;

ADULT; AGED; AGING; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER SURVIVAL; COHORT ANALYSIS; CONSERVATIVE TREATMENT; CONTROLLED STUDY; DISEASE SEVERITY; FOLLOW UP; GLEASON SCORE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCIDENTAL FINDING; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; MULTIVARIATE ANALYSIS; POPULATION RESEARCH; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSTATE CARCINOMA; PROTEIN DETERMINATION; SWEDEN; TRANSURETHRAL RESECTION; TUMOR VOLUME; UNIVARIATE ANALYSIS;

AGED; FOLLOW-UP STUDIES; HUMANS; INCIDENTAL FINDINGS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSTATIC NEOPLASMS; TIME FACTORS;

EID: 34247130089     PISSN: 00365599     EISSN: 16512065     Source Type: Journal    
DOI: 10.1080/00365590600991268     Document Type: Article

References (19)

1. Tombal B, De Visccher L, Cosyns JP, Lorge F, Opsomer R, Wese FX, et al. Assessing the risk of unsuspected prostate cancer in patients with benign prostatic hypertrophy: a 13-year retrospective study of the incidence and natural history of T1a-T1b prostate cancers. BJU Int 1999;84:1015-20.
2. Fowler JE Jr, Pandey P, Bigler SA, Yee DT, Kolski JM. Trends in diagnosis of stage T1a-b prostate cancer. J Urol 1997;158:1849-52.
3. Zigeuner RE, Lipsky K, Riedler I, Auprich M, Schips L, Salfellner M, et al. Did the rate of incidental prostate cancer change in the era of PSA testing? A retrospective study of 1127 patients. Urology 2003;62:451-5.
4. Ward JF, Bartsch G, Sebo TJ, Pinggera GM, Blute ML, Zincke H. Pathologic characterization of prostate cancers with a very low serum prostate specific antigen (0-2 ng/mL) incidental to cystoprostatectomy: is PSA a useful indicator of clinical significance? Urol Oncol 2004;22:40-7.
5. International Union Against Cancer. TNM classification of malignant tumours, 6th ed. Geneva, Switzerland: International Union Against Cancer; 2002.
6. Sebo TJ, Cheville JC, Riehle DL, Lohse CM, Pankratz VS, Myers RP, et al. Perineural invasion and MIB-1 positivity in addition to Gleason score are significant preoperative predictors of progression after radical retropubic prostatectomy for prostate cancer. Am J Surg Pathol 2002;26:431-9.
7. Stricker HJ, Jay JK, Linden MD, Tamboli P, Amin MB. Determining prognosis of clinically localized prostate cancer by immunohistochemical detection of mutant p53. Urology 1996;47:366-9.
8. Krupski T, Petroni GR, Frierson HF Jr, Theodorescu JU. Microvessel density, p53, retinoblastoma, and chromogranin A immunohistochemistry as predictors of disease-specific survival following radical prostatectomy for carcinoma of the prostate. Urology 2000;55:743-9.
9. Sandblom G, Dufmats M, Olsson M, Varenhorst E. Validity of a population-based cancer register in Sweden - an assessment of data reproducibility in the South-East Region Prostate Cancer Register. Scand J Urol Nephrol 2003;37:112-9.
10. Sandblom G, Dufmats M, Nordenskjold K, Varenhorst E. Prostate carcinoma trends in three counties in Sweden 1987-1996: results from a population-based national cancer register. South-East Region Prostate Cancer Group. Cancer 2000;88:1445-53.
11. Gleason DF, Mellinger GT. Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 1974;111:58-64.
12. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Prognostic value of the Gleason score in prostate cancer. BJU Int 2002;89:538-42.
13. Varenhorst E, Alund G. Urethral obstruction secondary to carcinoma of prostate: response to endocrine treatment. Urology 1985;25:354-6.
14. Aus G, Abbou CC, Bolla M, Heidenreich A, Schmid HP, van Poppel H, et al. EAU guidelines on prostate cancer. Eur Urol 2005;48:546-51.
15. Cheng L, Bergstralh EJ, Scherer BG, Neumann RM, Blute ML, Zincke H, et al. Predictors of cancer progression in T1a prostate adenocarcinoma. Cancer 1999;85:1300-4.
16. Josefsson A, Wikstrom P, Granfors T, Egevad L, Karlberg L, Stattin P, et al. Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment. Eur Urol 2005;48:577-83.
17. Stattin P, Damber JE, Karlberg L, Bergh A. Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer. J Urol 1997;157:219-22.
18. Aaltomaa S, Lipponen P, Vesalainen S, Ala-Opas M, Eskelinen M, Syrjanen K. Value of Ki-67 immunolabelling as a prognostic factor in prostate cancer. Eur Urol 1997;32:410-5.
19. Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. JAMA 2004;291:2713-9.